Navigation Links
Advanced Cell Technology's Ability to Rescue Vision in Blind Rats,Noted in Scientific American

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 5, 2007 - Advanced Cell Technology, Inc.'s (OTCBB: ACTC) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU).

The article is available at the following link: http://www.sciam.com/article.cfm?chanID=sa006&articleID=C74A4206-E7F2- 99DF-3D2B8FC2C6B5D74C&colID=5 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).

Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."

One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify the risk of injecting forei gn, or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.

Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contact

The Investor Relations Group
Investors:
James Carbonara, 212-825-3210
or
Media:
Bill Douglass, 212-825-3210


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 Report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/24/2017)... Australia , Feb. 23, 2017  Directors from Pharma To ... two companies have joined forces, resulting in the founding of Pharma ... Pharma To Market are pleased to announce their expansion ... office in Singapore . The company are delighted ... as Co-Director of the Singapore based entity. ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... leadership , media relations, content marketing, social media management, corporate communications, SEO and ... in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism and ... for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. ... to see films in an environment that accommodates their unique needs. , Launched ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
Breaking Medicine News(10 mins):